Every year, an estimated 400,000 children worldwide develop a form of cancer, with stark differences in survival rates between high-income and low-income countries.
Luke Thomas, CEO of World Child Cancer, stated that low- to middle-income countries often receive lower quality medicines, effectively prescribing 'hope and a death sentence'.
The average five-year survival rate for children with cancer in low- and middle-income countries is less than 20%, highlighting a systemic healthcare imbalance.
While effective medicines exist for childhood cancers, expensive treatments and unreliable generics lead to significant disparities in survival outcomes for children globally.
Collection
[
|
...
]